Experienced in Myelofibrosis

Yu H. Ren

No. 277 Yanta West Road, 
Xi'an, CN 
Experienced in Myelofibrosis
No. 277 Yanta West Road, 
Xi'an, CN 
OverviewLocationsClinical Research

Overview

Yu Ren practices in Xi'an, China. Ren is rated as an Experienced expert by MediFind in the treatment of Myelofibrosis. Their top areas of expertise are Breast Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Glioblastoma, Astrocytoma, and Mastectomy.

Their clinical research consists of co-authoring 208 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Myelofibrosis.

Locations

No. 277 Yanta West Road, Xi'an, 710061, China
Other Locations
277 West Yanta Road, Xi'an, 710061, China
102 Xuefu Street, Taiyuan, 030006, China
277 Yanta Western Rd, Xi'an, 710061, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3

208 Total Publications

Implication of Angio-based Microvascular Resistance, a Measure of Coronary Microvascular Dysfunction Severity, for Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy.
Implication of Angio-based Microvascular Resistance, a Measure of Coronary Microvascular Dysfunction Severity, for Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy.
Journal: The American journal of cardiology
Published: June 11, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ren's expertise for a condition
ConditionClose
      View All 33 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile